News | April 25, 2024
New chemical method could cut waste from drug production
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Open a printable version of this pageEmail the URL of this page to a friend
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Subscribe To Our Newsletter & Stay Updated
